# Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

> **NCT05552755** · PHASE1,PHASE2 · RECRUITING · sponsor: **Recursion Pharmaceuticals Inc.** · enrollment: 67 (estimated)

## Conditions studied

- Familial Adenomatous Polyposis

## Interventions

- **DRUG:** REC-4881
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05552755
- **Lead sponsor:** Recursion Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-10
- **Primary completion:** 2027-06
- **Final completion:** 2027-09
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552755, "Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05552755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*